News Immutep ADR Nasdaq

Equities

IMMP

US45257L1089

Market Closed - Nasdaq Other stock markets 01:30:00 08/06/2024 am IST			5-day change	1st Jan Change
2.67 ^USD	-6.32%		-10.40%	+11.25%

05/06	Immutep Completes Stock Offering	MT
03/06	Immutep, Merck Collaborate on Trial for Lung Cancer Therapy	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immutep Completes Stock Offering	06/06	MT
Immutep : successfully completes institutional placement and institutional component of entitlement offer	05/06	PU
Immutep, Merck Collaborate on Trial for Lung Cancer Therapy	03/06	MT
Immutep, Merck Partner for Efti and Keytruda Combo in Lung Cancer Trial	03/06	MT
Immutep Raising AU$100 Million for Phase Three Trial	03/06	MT
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial	03/06	AQ
Immutep Limited Announces Clinical Collaboration with Msd to Evaluate Efti in Combination with Keytruda®? (Pembrolizumab) in Pivotal Phase Iii Trial	03/06	CI
Capital One Initiates Immutep at Overweight Rating With $10 Price Target	17/05	MT
Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data	15/05	MT
Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024	15/05	AQ
Immutep Limited Presents Data from Safety Lead-In Phase of AIPAC-003 at ESMO Breast 2024	15/05	CI
Immutep : ESMO Breast 2024 AIPAC 003 Poster (Metastatic Breast Cancer)	15/05	PU
Immutep Limited Announces Initial Clinical Data from EFTISARC-NEO	03/05	CI
Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma	02/05	AQ
Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma	02/05	CI
Immutep Validates Initial Efficacy of Immunotherapy Medication in Phase Two Cancer Trial	02/05	MT
Immutep Limited Provides an Update on the Ongoing Development of its Product Candidates, eftilagimod Alpha and IMP761 for the Quarter Ended 31 March 2024	30/04	CI
Canaccord Starts Immutep at Buy, Price Target is AU$1.00	30/04	MT
Immutep Quarterly Activities Report Q3 FY24	29/04	AQ
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Phase IIb Trial Evaluating Efti in Combination With KEYTRUDA in First Line Metastatic Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression	25/04	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Immutep ADR Nasdaq

Equities

IMMP

US45257L1089

Summary

Filters